2. Antibody-drug Conjugate/ADC Related Cell Cycle/DNA Damage
  3. Antibody-Drug Conjugates (ADCs) Antifolate
  4. Mirvetuximab soravtansine (solution)

Mirvetuximab soravtansine (solution)  (Synonyms: IMGN853 (solution))

Cat. No.: HY-132258A Pureza: 97.25%
COA
SDS
Instrucciones de manejo Technical Support

Mirvetuximab soravtansine (IMGN853) solution is an anti-folate receptor α (FRα) antibody drug-conjugate (ADC) consisting of the cytotoxic maytansinoid, DM4, covalently linked to the humanized monoclonal antibody M9346A, and the drug-linker conjugate for ADC is sulfo-SPDB-DM4 (HY-101141). Mirvetuximab soravtansine selectively binds to folate receptor 1 (FOLR1). Mirvetuximab soravtansine has an anti-proliferative effect via growth arrest and augmented DNA damage.

Para uso exclusivo en investigación. No vendemos a pacientes.

No. CAS : 1453084-37-1

Tamaño Precio Stock Cantidad
1 mg En stock
5 mg En stock
10 mg En stock
50 mg   Obtener un presupuesto  
100 mg   Obtener un presupuesto  

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Revisión del cliente

Based on 3 publication(s) in Google Scholar

Mirvetuximab soravtansine (solution) Related Antibodies

Top Publications Citing Use of Products
Cell Proliferation/Viability Assay
Apoptosis Analysis
Bio/Physico-chemical Assay

    Mirvetuximab soravtansine (solution) purchased from MedChemExpress. Usage Cited in: Cells. 2025 Feb 15;14(4):287.  [Abstract]

    Mirvetuximab soravtansine (MIRV; 1.56-50 nM; 72 h). TCam2_R_SK cisplatin-resistant seminoma cells were treated with increasing doses of MIRV in vitro.

    Mirvetuximab soravtansine (solution) purchased from MedChemExpress. Usage Cited in: Cells. 2025 Feb 15;14(4):287.  [Abstract]

    Mirvetuximab soravtansine (MIRV; 12.5 nM; 0-72 h). Green fluorescent NLG-2102Ep_R_NL cells were cultured, whether alone or in coculture, with red fluorescent NLR-NOY1_R_SK cells with or without 12.5 nM MIRV. The cell number of the green 2102Ep_R_NL cells was evaluated using live-cell imaging in a kinetic proliferation assay.

    Mirvetuximab soravtansine (solution) purchased from MedChemExpress. Usage Cited in: Cells. 2025 Feb 15;14(4):287.  [Abstract]

    Mirvetuximab soravtansine (MIRV; 3.13-12.5 nM; 72 h). Live-cell imaging assays confirmed a significant decrease in the cell number of NLR-JEG3_R_SK choriocarcinoma cells upon treatment with a 3.13nM dose of MIRV.

    Mirvetuximab soravtansine (solution) purchased from MedChemExpress. Usage Cited in: Cells. 2025 Feb 15;14(4):287.  [Abstract]

    Mirvetuximab soravtansine (MIRV; 500 nM; 96 h). Induction of apoptosis via MIRV in cisplatin-resistant NT2_R_SK cells. NT2_R_SK (EC) cells were treated with 500 nM of MIRV or 2.5 µM of CPT in vitro.

    Mirvetuximab soravtansine (solution) purchased from MedChemExpress. Usage Cited in: Cells. 2025 Feb 15;14(4):287.  [Abstract]

    Mirvetuximab soravtansine (MIRV; 1.56-50 nM; 72 h). MIRV induced a decrease in cell impedance, as a readout of cytolysis was determined in a kinetic-based impedance assay.

    • Actividad biológica

    • Pureza y Documentación

    • Referencias

    • Revisión del cliente

    Descripciòn

    Mirvetuximab soravtansine (IMGN853) solution is an anti-folate receptor α (FRα) antibody drug-conjugate (ADC) consisting of the cytotoxic maytansinoid, DM4, covalently linked to the humanized monoclonal antibody M9346A, and the drug-linker conjugate for ADC is sulfo-SPDB-DM4 (HY-101141). Mirvetuximab soravtansine selectively binds to folate receptor 1 (FOLR1). Mirvetuximab soravtansine has an anti-proliferative effect via growth arrest and augmented DNA damage[1].

    In Vitro

    Mirvetuximab soravtansine (IMGN853; 8 nM; 6 h; IGROV-1 cells) combined with Carboplatin (HY-17393) promotes synergistic growth inhibitory effects and cell cycle perturbations in vitro[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Mirvetuximab soravtansine (solution) Related Antibodies
    In Vivo

    Mirvetuximab soravtansine (IMGN853; 5 mg/kg; i.v.; female severe combined immunodeficient (SCID) mice with patient-derived xenografts) potentiates the antitumor activity of Carboplatin in vivo[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Ensayo clínico
    Peso molecular

    150000 (average)

    No. CAS
    Appearance

    Liquid

    Color

    Colorless to light yellow

    SMILES

    [Mirvetuximab soravtansine (solution)]
    Envío

    Shipping with dry ice.
    Almacenamiento

    -80°C, protect from light
    Pureza y Documentación

    Purity: 98.20%

    SDS (251 KB)

    COA (232 KB) SEC-HPLC (140 KB)

    Instrucciones de manejo (2659 KB)
    Referencias
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Mirvetuximab soravtansine (solution) Related Classifications

    • Calculadora de molaridad

    • Calculadora de dilución

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Mirvetuximab soravtansine (solution)1453084-37-1IMGN853 (solution)Antibody-Drug Conjugates (ADCs)AntifolateAntibody-Drug ConjugatesInhibitorinhibitorinhibit

    Productos vistos recientemente:

    Consulta en línea

    Your information is safe with us. * Required Fields.

    Nombre del producto

    		  

    Requested Quantity *

    Nombre del solicitante *

    		 

    Saludo

    Direcciòn del E-mail *

    		 

    Número de teléfono *

    Department

    		 

    Nombre de la Organizaciòn *

    City

    Provincia

    Country or Region *

    		      

    Observaciones

    Consulta para venta a granel

    Inquiry Information

    Nombre del producto:
    Mirvetuximab soravtansine (solution)
    Cat. No.:
    HY-132258A
    Cantidad:
    MCE Japan Authorized Agent:

    Revisión del cliente

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Nombre del producto

    		  

    Lot #

    Nombre del solicitante *

    		 

    Direcciòn del E-mail *

    Número de teléfono

    		 

    Department *

    Nombre de la Organizaciòn *

    		 

    Country or Region *

    Observaciones

    SAFETY DATA SHEET (SDS)

    English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.